BrainQ

• BrainQ is a neurotech company developing brainwave-based technologies (e.g. for neurorehabilitation).¹
• A Times of Israel piece highlighted a patient-advocacy and parent perspective: “Brainwave Pioneer: Time is Running out for My Son,” aligning with regulatory or access urgency for the technology.^{1 1}

Gardner updates

• BRAIN.Q launched a home-based AI brain recovery service in Israel (The Jerusalem Post), expanding access and commercial model for neurorehabilitation and neurotech deployment. ²
• The core technology is the Q Therapeutic System (BQ 3.0): a wearable helmet delivering low-intensity, frequency-tuned extremely-low-frequency electromagnetic fields (ELF-EMF) that target damaged neural networks and promote neuroplasticity, paired with a cloud-based AI platform enabling remote clinician monitoring.²
• The system has received FDA Breakthrough Device Designation, CE Mark certification in the EU, and AMAR approval from Israel’s Health Ministry as a prescribed therapy for reducing post-stroke disability.²
• Key clinical data: a meta-analysis presented at the American Heart Association’s International Stroke Congress found that 34% of patients with moderate-to-severe disability achieved full functional independence (vs. 12% in controls); approximately 85% of treated patients showed measurable improvement; over 8,000 sessions conducted with no serious adverse events.²
• Pivotal trial EMAGINE 2.0 (NCT06386874) is a multicenter RCT enrolling 100–122 adults with subacute ischemic stroke (mRS 3–4, FMA-UE 10–45) across ~20 U.S. centers; treatment is 5×/week with BQ 3.0; the trial started August 2024 with completion targeted July 2026.³
• Total funding exceeds $50 million, including a $40 million Series C led by Hanaco Ventures with Dexcel Pharma and Peregrine Ventures; the company also received €17.5 million from the European Commission’s EIC Accelerator, one of the first companies selected.⁴
• The Israeli commercial model is subscription-based (₪2,000 setup + ₪2,500/month) with a minimum 6-month commitment; patients receive the device at home after a prescription and clinician-guided onboarding session.⁵
• Clinical trials are also underway at University of Florida and Burke Rehabilitation Hospital evaluating BQ 3.0 for chronic stroke recovery (as of 2025); earlier animal studies established that theta-frequency ELF-EMF (5 Hz) significantly enhances motor recovery while gamma (40 Hz) does not.³

Footnotes

1. https://news.google.com/rss/articles/CBMiiAFBVV95cUxOUG1EN1otc1BYZnJOc1ZlVFNMOE1XTEtHOTBPTWZUUllSY05pM1h3RFNUVERHYU1jaWVlZVpKV29COTRybnpva2ZRNi13dDY2MEZfOXpFalFmTEhqQkNqcU9yY21fbnVqTFdNM19nODhCSWFycmQ4OHdaTk5pV1JzblVrRUEtSmlN?oc=5 ↩ ↩² ↩³

2. https://www.jpost.com/business-and-innovation/article-887859 ↩ ↩² ↩³ ↩⁴

3. https://synapse.patsnap.com/organization/074bbb541689880a16e8dfb1f54fc083 ↩ ↩²

4. https://www.fiercebiotech.com/medtech/brainq-reels-40m-to-trial-ai-powered-electromagnetic-field-therapy-device-for-stroke ↩

5. https://www.brainq.co.il ↩